Monte Rosa Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Monte Rosa Therapeutics, Inc. (GLUE) had Debt Securities, Available-for-sale, Amortized Cost of $532.28 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $532.28M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $507.17M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $247.06M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $182.84M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $532.28M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $507.17M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $247.06M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $182.84M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $221.17M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $247.45M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $147.78M 10-K · filed 2026-03-17 |
| 2024-09-30 | $116.37M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $153.43M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $93.20M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $104.36M 10-K · filed 2025-03-20 |
| 2023-09-30 | $119.61M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $156.40M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $179.99M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $208.36M 10-K · filed 2024-03-14 |
| 2022-09-30 | $160.44M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $190.98M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $179.00M 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |